PNGM Net Income from 2010 to 2026
| PNGM Stock | USD 0.0001 0.00 0.00% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -384.3 K | Current Value -403.5 K | Quarterly Volatility 77.1 K |
Check Er Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Er Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 205.2 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. PNGM financial statements analysis is a perfect complement when working with Er Therapeutics Valuation or Volatility modules.
PNGM | Net Income | Build AI portfolio with PNGM Stock |
Evaluating Er Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Er Therapeutics's fundamental strength.
Latest Er Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Er Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Er Therapeutics financial statement analysis. It represents the amount of money remaining after all of Er Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Er Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Er Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (426.95 K) | 10 Years Trend |
|
Net Income |
| Timeline |
PNGM Net Income Regression Statistics
| Arithmetic Mean | (404,321) | |
| Coefficient Of Variation | (19.07) | |
| Mean Deviation | 37,276 | |
| Median | (426,953) | |
| Standard Deviation | 77,117 | |
| Sample Variance | 5.9B | |
| Range | 318.6K | |
| R-Value | (0.33) | |
| Mean Square Error | 5.6B | |
| R-Squared | 0.11 | |
| Significance | 0.19 | |
| Slope | (5,054) | |
| Total Sum of Squares | 95.2B |
PNGM Net Income History
Other Fundumenentals of Er Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
About Er Therapeutics Financial Statements
Er Therapeutics investors utilize fundamental indicators, such as Net Income, to predict how PNGM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Er Therapeutics Correlation against competitors. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Will Diversified Metals & Mining sector continue expanding? Could PNGM diversify its offerings? Factors like these will boost the valuation of Er Therapeutics. Anticipated expansion of PNGM directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Er Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Er Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Er Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Er Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Er Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Er Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Er Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.